LA JOLLA, CALIFORNIA, March 2, 2017 – INmune Bio, Inc., a cancer immunotherapy company focused on developing therapies that prime natural killer (NK) cells to attack cancer, today announces its co-founder, Professor Mark Lowdell, PhD, FRCPath FRSB, has been named one of Europe’s 10 academic-entrepreneur superstars by Labiotech, the leading digital media covering the European Biotech industry.
“I was surprised and delighted to be named one of the elite academic-entrepreneurs in this field in Europe. I have been fortunate to be able to work alongside academic and commercial collaborators to develop a number of scientific discoveries that have the prospect of becoming successful therapies able to make a difference in the lives of patients,” stated Professor Lowdell.
Professor Lowdell is the Professor of Cell & Tissue Therapy and Director of the Centre for Cell, Gene & Tissue Therapy at the Royal Free London NHS FT and University College London. He is an established leader in the development of cell and tissue medicines for immunotherapy and regenerative medicine and has been responsible for the development and delivery of multiple cell-based therapies both academically and commercially. In addition to being a co-founder of INmune Bio, Professor Lowdell is also the Company’s chief scientific officer and chair of the Scientific Advisory Board.
Professor Lowdell is also a founder-shareholder of CellMedica Ltd. and a member of its scientific advisory board. In 2016 he became a co-founder of Achilles Therapeutics, an immunotherapy company funded by Syncona, the venture fund of the Wellcome Trust. He is a consultant to multiple biopharma companies and contract manufacturers across the field of cell and tissue therapy.
Professor Lowdell holds a PhD in clinical immunology from the University of London and fellowships from the Royal College of Pathologists (immunopathology) and the Royal Society of Biology. He is the current vice president (EU- Middle East) of the International Society for Cell Therapy.
Dr. RJ Tesi, MD, CEO and co-founder of INmune Bio, commented, “Mark has a rare combination of having the intellect of a consummate academic scientist as well as the knowledge of a successful entrepreneur when he looks at the practical, regulatory and technical challenges of delivering and then commercializing novel therapies from the lab bench. All of us at INmune Bio look forward to his continued insight, innovation and experience.”
INmune Bio’s lead candidate is INKmune™, a novel biologic therapy that primes the patient’s NK cells to attack their cancer. In pre-clinical studies, INKmune has been shown to attack many types of hematologic malignancies including leukemia, lymphoma, multiple myeloma and epithelial cancers including breast, ovarian, prostate, renal and lung cancer. INmune expects to begin clinical trials of INKmune™ by year-end 2017.
About INmune Bio
INmune Bio is a private clinical stage biotechnology company developing therapies for targeting the innate immune system. INmune Bio is developing INKmune™, a novel therapy that harnesses the patient’s own NK cells to attack their cancer. INmune is targeting residual disease - the cancer cells that survive initial treatments that return to cause the cancer relapse which may cause death. Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells’ ability to eliminate residual disease.
For more information visit www.inmunebio.com
Labiotech is the leading digital media covering the European Biotech industry. Over 70,000 people use it monthly to keep a watch on the business and innovations of biotechnologies.
For more information visit www.labiotech.eu
Forward-looking statements: This press release contains certain "forward-looking statements." Such statements may include statements relating the leadership of the company and other statements relating to future events or to the company's future financial performance and are not historical facts, including statements which may be preceded by the words "intends," "may," "will," "plans," "expects,” "anticipates," “projects," "predicts," "estimates," "aims,” "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance and are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the company. Actual results may differ materially from the expectations contained in the forward-looking statements. More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company's Private Placement Memorandum. The company does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
David Moss, CFO
The Del Mar Consulting Group, Inc.
Robert B. Prag, President